BCG Induces PD-1 Upregulation on Circulating CD8+T Cells and IL-6 and IL-8 Secretion In VitroOA
Backgrounds:Bacillus Calmette-Guérin(BCG)remains the most effective adjuvant therapy for non-muscle-invasive bladder cancer(NMIBC);however,the immunological underpinnings of its efficacy remain incompletely understood.This study aims to elucidate the dual immunomodulatory roles of BCG by integrating systemic and tumor-intrinsic analyses,through determining the systemic effects of BCG instillation on immune checkpoint expression and direct inflammatory response in a previously established in vitro tumor model.Methods:We investigated systemic and tumor-intrinsic immune responses to BCG.Flow cytometry was used to evaluate immune checkpoint expression on circulating lymphocyte subsets in NMIBC patients(n=7)at various stages of BCG therapy.In parallel,an in vitro model of PD-L1 modulation using breast cancer cell lines(MDA-MB-231 and MCF-7)was stimulated with BCG and TLR agonists,and the secretion of IL-6 and IL-8 was assessed using an ELISA.Results:Peripheral immune profiling revealed stable lymphocyte frequencies,but a significant increase in PD-1 expression on CD8^(+)T cells following BCG exposure(p=0.0068),with no significant modulation in CTLA-4 levels.In vitro,MDA-MB-231 cells exhibited robust IL-6 secretion upon high-dose BCG stimulation(p=0.0277),whereas MCF-7 cells showed increased IL-8 release(p<0.0001).Other TLR agonists had limited effects.Conclusions:BCG induces dual immunomodulation,characterized by PD-1 upregulation in systemic CD8^(+)T cells and the release of pro-inflammatory cytokines from epithelial tumor cells.These findings support the potential of combining BCG with immune checkpoint inhibitors and underscore IL-6 and IL-8 as candidate biomarkers of tumor-intrinsic responsiveness.
Gabriela R.Barbosa;Luciana S.B.Dal Col;Caroline C.Bighetto;Maria Carolina X.de Godoy;Marina D.B.P.Campioni;Marcus V.Sadi;Alessandra Gambero;Leonardo O.Reis
Immuno-Oncology,Pontifical Catholic University of Campinas(PUC-Campinas),Campinas,SP,Brazil INCT UroGen,National Institute of Science,Technology and Innovation in Genitourinary Cancer(INCT),Campinas,SP,BrazilPaulista School of Medicine,Federal University of São Paulo,São Paulo,SP,Brazil UroScience,State University of Campinas(Unicamp),Campinas,SP,BrazilImmuno-Oncology,Pontifical Catholic University of Campinas(PUC-Campinas),Campinas,SP,BrazilImmuno-Oncology,Pontifical Catholic University of Campinas(PUC-Campinas),Campinas,SP,BrazilUroScience,State University of Campinas(Unicamp),Campinas,SP,BrazilINCT UroGen,National Institute of Science,Technology and Innovation in Genitourinary Cancer(INCT),Campinas,SP,Brazil Paulista School of Medicine,Federal University of São Paulo,São Paulo,SP,BrazilImmuno-Oncology,Pontifical Catholic University of Campinas(PUC-Campinas),Campinas,SP,Brazil INCT UroGen,National Institute of Science,Technology and Innovation in Genitourinary Cancer(INCT),Campinas,SP,BrazilImmuno-Oncology,Pontifical Catholic University of Campinas(PUC-Campinas),Campinas,SP,Brazil INCT UroGen,National Institute of Science,Technology and Innovation in Genitourinary Cancer(INCT),Campinas,SP,Brazil UroScience,State University of Campinas(Unicamp),Campinas,SP,Brazil
医药卫生
BCG immunotherapybreast cancerToll-like receptors agonistsbladder cancer
《Oncology Research》 2026 (7)
P.484-496,13
National Council for Scientific and Technological Development,CNPq,Research Productivity,grant number:#310135/2022-2 and INCT-UROGEN#408576/2024-3(Reis LO)the São Paulo Research Foundation(FAPESP)INCT-UROGEN grant number FAPESP#25/26851-4(Reis LO).
评论